anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Elevated factor VIII activity level above the ULN as measured by the chromogenic substrate assays (CSA), or one-stage clotting assays (OSA), or both assays has occurred following ROCTAVIAN administration. Thirty-eight (28%) patients experienced elevations of factor VIII above ULN with a median time to first occurrence of 14 weeks and a median total duration above ULN of 12 weeks.

An increase in factor VIII activity may increase the risk for venous and arterial thromboembolic events. There are no data in patients with a history of venous or arterial thromboembolism or known history of thrombophilia since such patients were excluded from clinical trials of ROCTAVIAN.

Evaluate patients for risk of thrombosis including general cardiovascular risk factors before and after administration of ROCTAVIAN. Advise patients on their individual risk of thrombosis in relation to their factor VIII activity levels above ULN and consider prophylactic anticoagulation. Advise patients to seek immediate medical attention for signs or symptoms indicative of a thrombotic event.
Dual tDCS: the anodal tDCS will be applied over the M1 of the lesioned hemisphere, while the cathodal tDCS will be applied over the M1 of the non-lesioned hemisphere for 20 mins before physical therapy (about 1 hours). Current intensity is fixed at 2 mA and current will flow continuously. Physical therapist will give an intervention program for lower limb performence.
The invention belongs to a traditional Chinese medicine, and specifically relates to a traditional Chinese medicine for treating insomnia. The traditional Chinese medicine is characterized by consisting of the following components in parts by weight: 4-6 parts of salvia miltiorrhiza and 4-6 parts of brown sugar. The traditional Chinese medicine is prepared by taking 100 g of cleaned and dried salvia miltiorrhiza, grinding into 100 meshes of a fine powder, adding fine brown sugar and mixing uniformly to prepare a medicine powder. A proper amount of the medicine powder is directly taken 2-3 times every day. According to traditional Chinese medicine syndrome differentiation theory, the traditional Chinese medicine has the advantages of being simple in composition, easily available in materials, low in cost, high in cure effect and none in toxic and side effects. Because the traditional Chinese medicine has efficacies of calming heart and relieving nerve, the body is adjusted to a normal sleep state and the traditional Chinese medicine has wide-spectrum practicality.
In this study, investigators have developed a novel CAR T cell system targeting mesothelin (MSLN) antigen, termed as Pan-T booster (harbouring CD40 agonist and one T cell costimulator agonist) co-expressing MSLN CAR T cell. Preclinical study demonstrated that this novel pan-T booster co-expressing MSLN CAR T cell possess more powerful antitumor activity than previously reported MSLN-CAR T cells. In this clinical trial, enrolled patients receive an initial dose of pan-T booster co-expressing MSLN CAR T cells at 1×10\^6 cells/kg based on the basic principle of dose escalation design, in order to evaluate the safety, feasibility, pharmacokinetics/pharmacodynamics, and efficacy of pan-T booster co-expressing MSLN CAR T cell in vivo. The level of CAR-T cell expansion and the duration of expansion are important determining factors for subsequent dose escalation infusions (3×10\^6 cells/kg and 6×10\^6 cells/kg). Repeated infusion, immune checkpoint inhibitor (such as anti-PD1/PD-L1) or local therapy (radiotherapy) are allowed when patients achieve clinical benefit and the level of CAR-T cell expansion declines to low level.

In the 3 patients receiving the first dose treatment, we observed high levels of expansion of both total T cells and CAR T cells in the PB after CAR T cell infusion (CAR T \> 300 per microliter, total T cells reaching 10 times the number of CAR T cells), one patient experienced a grade 2 pulmonary toxicity and transient liver dysfunction during the CAR T cell expansion period (infusion 14 days later), transient marked enlargement of the spleen, and required to be treated with glucocorticoids and ruxolitinib to control T cell toxicity. Efficacy monitoring showed that some target lesion clearance or reduction could be achieved within 2-4 weeks after CAR T infusion. Based on these observations, it was concluded that low-dose CAR T infusion (CAR+T cells 1×10\^6 cells/kg) could achieve the sufficient level of CAR T cell expansion, and the initially planned CAR T dose escalation was dispensable. Subsequent patients after May 10th, 2024, will all be treated using 1×10\^6 cells/kg dose.
Aging causes responsible endothelial changes, in part by a decrease in the blood flow of the skeletal muscles of the elderly. Reduction of muscle mass / function (Sarcopenia) and Diabetes Mellitus are frequent pathologies in the elderly. L-Arginine is a semi-essential amino acid precursor to nitric oxide synthesis (NO), an important vasodilator and protector cardiovascular.

Seventy-five women were allocated into three groups: twenty-five healthy young (HY) recruited among University students, and fifty women elderly, this was stratified in twenty-five healthy elderly (HE) control and twenty-five with hyperglycemia (HG) elderly from the ambulatories of the Geriatric and Diabetology at the State University of Rio de Janeiro (UERJ) and private supplementary health program. To control group was considered absence cardiovascular risk factor except advanced age. Participants were subjected to screening phase before being eligible for the study by telephone, which comprised of individual clinical history. All subjects signed the written Informed Consent Form enclosed in the protocol approved by Ethics Committee from the State University of Rio de Janeiro according to Helsinki Declaration.

The subjects elected for research made 4 visits to the Biovasc laboratory for data collection. First day: the protocol was explained and agreement from the voluntary obtained, followed and anamnesis and physical exam that included measure at-rest blood pressure, weight and height. Moreover, women examined after 6 hours fasting the microcirculation function using nailfold vidiocapilaroscopy (NVC), followed of the measure of forearm blood flow (FBF) and vascular reactivity by venous occlusion plethysmography (VOP). Second day: Venous blood sample collection after 12 hours fasting. In sequence, they realized whole-body dual-energy X-ray absorptiometry (DXA) to calculate the body composition main measure lean and fat mass. After, was delivered a box with 14 sachets content 5g L-arginine supplementation, and it was recommended to ingest with water 30 minutes before breakfast during 14 days. Third day: Return after the supplementation to realize measurement weight, and exams NVC and VOP. Fourth day: blood sample were taken after 12 hours fasting under effect of the L-arginine.
A data processing tool for the viewing of real-time, critical patient data on remote and/or mobile devices. The tool efficiently renders graphical data on the screen of the remote device in a manner that makes it practical for the health care provider to accurately and timely review the data for the purpose of making an informed decision about the condition of the patient. Charting control is established and implemented using the latest GDI+, GAPI and PDA drawing techniques. The charting components provide landscape support, an ability to overlay patient data and patient images, zoom in/zoom out, custom variable speed scrolling, split screen support, and formatting control. The methodology operates as an asynchronous application. The methodology allows the critical patient data to be streamed in real-time to the handheld device. Finally, the methodology implements an IT management console that allows system managers to monitor the exchange of data between hospital systems and the primary database, including all patient data packets, notifications and alerts, connected remote devices, etc.
Yondelis once every 3 weeks schedule: 1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle. Patients will be pretreated with 20 mg of dexamethasone i.v. on Day 1 of each treatment cycle 30 minutes prior to each infusion.
A woman in her 30s presented to emergency with complaints of acute lower abdominal pain for 3 days, not associated with any menstrual, bowel or urinary symptoms. Examination revealed an abdominopelvic mass corresponding to an 18-week gravid uterus with diffuse tenderness and guarding over her lower abdomen. The patient was a follow-up case of subserosal fibroid uterus, chronic kidney disease stage 4 and rheumatic heart disease on anticoagulants. Fibroid degeneration or torsion was suspected. Ultrasound revealed a large posterior wall subserosal fibroid with free fluid in the pelvis. As findings did not suggest degeneration or pedunculated fibroid, noncontrast CT was done, which showed a similar mass with a pedicle arising from the uterine fundus with free fluid with no other evident cause of acute abdomen. The patient was taken up for emergency laparotomy. Intraoperatively, it was found to be a case of subserosal fibroid with greater omentum adhered to it and twisted around its axis about eight times. This case is being reported to highlight a rare cause of acute abdomen.
The invention provides methods and compositions for treatment of bacterial infections. The composition may be a combination of factors, which include A0, A1, B1, B2, CO, C1, isoB0, and MAG, in the presence of low level solvent. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimens include multiple dose administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection. Dosing regimens for renal patients are also included. ® KIPO & WIPO 2007
Compromised hepatic drug metabolism in response to proinflammatory cytokine release is primarily attributed to downregulation of cytochrome P450 (CYP) enzymes. However, whether inflammation also affects other phase I and phase II drug metabolizing enzymes (DMEs), such as the flavin monooxygenases (FMOs), carboxylesterases (CESs), and UDP glucuronosyltransferases (UGTs), remains unclear. This study aimed to decipher the impact of physiologically relevant concentrations of proinflammatory cytokines on expression and activity of phase I and phase II enzymes, to establish a hierarchy of their sensitivity as compared with the CYPs. Hereto, HepaRG cells were exposed to interleukin-6 and interleukin-1β to measure alterations in DME gene expression (24 h) and activity (72 h). Sensitivity of DMEs toward proinflammatory cytokines was evaluated by determining IC50 (potency) and Imax (maximal inhibition) values from the concentration-response curves. Proinflammatory cytokine treatment led to nearly complete downregulation of CYP3A4 (∼98%) but was generally less efficacious at reducing gene expression of the non-CYP DME families. Importantly, FMO, CES, and UGT family members were less sensitive toward interleukin-6 induced inhibition in terms of potency, with IC50 values that were 4.3- to 7.4-fold higher than CYP3A4. Similarly, 18- to 31-fold more interleukin-1β was required to achieve 50% of the maximal downregulation of FMO3, FMO4, CES1, UGT2B4, and UGT2B7 expression. The differential sensitivity persisted at enzyme activity level, highlighting that alterations in DME gene expression during inflammation are predictive for subsequent alterations in enzyme activity. In conclusion, this study has shown that FMOs, CESs, and UGTs enzymes are less impacted by IL-6 and IL-1β treatment as compared with CYP enzymes. SIGNIFICANCE STATEMENT: While the impact of proinflammatory cytokines on CYP expression is well established, their effects on non-CYP phase I and phase II drug metabolism remains underexplored, particularly regarding alterations in drug metabolizing enzyme (DME) activity. This study provides a quantitative understanding of the sensitivity differences to inflammation between DME family members, suggesting that non-CYP DMEs may become more important for the metabolism of drugs during inflammatory conditions due to their lower sensitivity as compared with the CYPs.
Nighttime driving presents a critical challenge to road safety due to insufficient lighting and increased risk of driver fatigue. Existing methods for monitoring driver fatigue, mainly focusing on behavioral analysis and biometric monitoring, face significant challenges under low-light conditions. Their effectiveness, especially in dynamic lighting environments, is limited by their dependency on specific environmental conditions and active driver participation, leading to reduced accuracy and practicality in real-world scenarios. This study introduces a novel 'Illumination Intelligent Adaptation and Analysis Framework (IIAAF)', aimed at addressing these limitations and enhancing the accuracy and practicality of driver fatigue monitoring under nighttime low-light conditions. The IIAAF framework employs a multidimensional technology integration, including comprehensive body posture analysis and facial fatigue feature detection, per-pixel dynamic illumination adjustment technology, and a light variation feature learning system based on Convolutional Neural Networks (CNN) and time-series analysis. Through this integrated approach, the framework is capable of accurately capturing subtle fatigue signals in nighttime driving environments and adapting in real-time to rapid changes in lighting conditions. Experimental results on two independent datasets indicate that the IIAAF framework significantly improves the accuracy of fatigue detection under nighttime low-light conditions. This breakthrough not only enhances the effectiveness of driving assistance systems but also provides reliable scientific support for reducing the risk of accidents caused by fatigued driving. These research findings have significant theoretical and practical implications for advancing intelligent driving assistance technology and improving nighttime road safety.
The invention discloses a preparation method of a Tibetan medicine for treating acquired immune deficiency syndrome. The Tibetan medicine comprises active components or the active components and pharmaceutically-acceptable auxiliary materials, wherein the active components are prepared by pure copper ash, semen hyoscyami paste, wood of shiny-leaved yellowhorn paste, Tibetan codonopsis pilosula, cortex berberidis, fructus podophylli and benzoin according to a certain weight ratio. The Tibetan medicine can be prepared into any one of common orally-taking drug forms. The Tibetan medicine has effects of clearing heat, removing toxicity, resolving hard lump, performing swelling subsidence and strengthening the body resistance. The Tibetan medicine mainly treats aeipathia, yellow water, the acquired immune deficiency syndrome, lymphopathy and eleven kinds of internal and external lumps in the abdomen referred by the Tibetan medicine. The Tibetan medicine considers that the root cause of all the aeipathia is indigestion, and digestion does not cause the aeipathia.
Embodiments relate to a medical information processing apparatus and a medical information processing method. Provided are a medical information processing device and a medical information processing method, which can improve the usefulness of diagnosis assistance. The medical information processing device of the embodiment is provided with an acquisition unit, an extraction unit, and a display control unit. The acquisition unit acquires a plurality of output data that are output from a plurality of analysis processes that have been input with medical image data as input data. The extraction unit selectively extracts a plurality of output data from the plurality of output data based on the extraction conditions. The display control unit controls to display a plurality of pieces of information corresponding to the plurality of pieces of output data extracted by the extraction unit and a medical image associated with any of the plurality of pieces of information and generated from the medical image data.
Peptides which have the sequence of SEQ ID NOS: 1, 2 or 3 or variants of these peptides are claimed. These are derived from p21<SP>WAF1</SP> corresponding to p21 C terminal amino acids 149-159 and typically contain the conserved region XLXF or variants upon this region. Such peptides are preferential inhibitors of the CDK2/cyclin complex rather than the CDK4/cyclin complex. In alternative embodiments of the invention many different amino acid substitutions are claimed, especially specific alanine replacements, as are cyclic forms of these peptides. The use of these compounds in medicaments is claimed. Assays for substances that bind or interact with cyclin/CDK complexes are alternatively claimed. Also claimed are drug screening assays for substances that bind in the cyclin groove or to specific cyclin A amino acids.
The study will consist of eight total interactions. We will allow for a 72 hour window for each encounter to allow for patient flexibility and scheduling. The first encounter will include medication education using the standardized tool. The remaining seven interactions will include toxicity and adherence assessment through patient interviews, the OCAS, pill counts, and pharmacy fill data. All interactions will be completed via telephonic outreach or televideo platform by either CRNP, PA-C or PharmD. The patient will be approached when an OCA is prescribed to be given a copy of the OncoLink® patient education material and consent form for review. Patients will be randomized 1:1 to either televideo or telephonic interactions using a block size of 4. All study staff will be blinded to block size. Once a patient is randomized, s/he will be scheduled for the series of follow up encounters via the assigned modality. The first telemedicine interaction will occur within 72 hours of the patient receiving their prescribed OCA(s) at which time the standardized educational information regarding the agent(s), dosing of the medication and potential medication side effects will be reviewed with the patient and/or caregiver. The second encounter will occur approximately 2 weeks after the patient starts the medication to assess for adherence and toxicity. The third through eighth encounters will take place every 2 weeks thereafter through the study timeframe up to four months. At each visit, an adherence assessment including pill count, and Oral Chemotherapy Adherence Scale (OCAS) (Bagcivan and Akbayrak 2015) will be completed per standard of care in addition to patient interview to assess adherence and toxicity. Fill history will be obtained prior to each interaction to verify medication possession ratio and proportion of days covered.

Each patient in the study will participate for a duration of up to 4 months. All of the research will take place at the Abramson Cancer Center at Penn Presbyterian Medical Center.
PURPOSE:The titled composition, prepared by incorporating a specific amount of an aliphatic alkanolamide in a composition for the oral cavity containing a compound having the astringency, and capable of improving the astringency and the feeling of use. CONSTITUTION:A composition for the oral cavity contaning prepared by incorporating an aliphatic alkanolamide, e.g. capric acid monoethanolamide, lauric acid diethanolamide or myristic acid diethanolamide, preferably the fatty acid alkanolamide having 8-18C fatty acid group and 2C or 3C alkanol group, in an amount of 1-3wt% based on the total weight of the composition in a composition for the oral cavity containing a compound having the astringency. Compounds such as a phosphoric ester, phosphonic acid active constituent, e.g. mesoinositol ester of hexanoic acid, gelling silica or aluminum compound may be  cited as the compound having the astringency. EFFECT:No astringent taste in gargling and irritation, and improved feeling of use and storage stability.
Cold snare polypectomy is an easy-to-apply technique and has been the most popular technique esprcially for small and diminutive polyps. Briefly, the endoscopist advances the snare sheath, opens the snare and encircles the polyp. The snare is then slowly and progressively closed, with the aim of capturing 1-2 mm of normal tissue around the polyp, until complete closure is achieved and the polyp is guillotined. The polyp can then be suctioned and retrieved for histologic assessment.
The goal of the project is to identify and characterize populations at risk for developing pulmonary arterial hypertension (PAH). The project will establish a PAH subphenotype core cohort (CORE) to evaluate mechanistic pathways and test novel therapeutic agents. This core cohort serves as a resource for the Translational Program Project grant, Vascular Subphenotypes of Lung Disease (Mark Gladwin, PI). In order to construct the CORE, we have chosen to recruit COPD and HIV patients, two populations with advanced lung and systemic diseases that are enriched for PAH. We have selected these as prototypic conditions because: A) both COPD patients and HIV-infected patients develop PAH at a rate significantly greater than the general population, B) morbidity and mortality are greatly increased in dually-affected persons, C) mechanisms responsible for development of the PAH "subphenotype" are not well-understood, D) clinical and genetic characteristics of the subgroup with PAH are not known, and E) effects of PAH therapies in subphenotypes are incompletely studied. There is also some overlap between COPD and HIV, with HIV-infected patients having accelerated COPD even with effective antiretroviral therapy. Participants with COPD, HIV, or HIV-uninfected controls will be recruited to the study based on entry criteria of elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) and/or an abnormal echocardiogram. These subjects will then undergo a 6-minute walk test, blood collection, questionnaire, medical record review, and echocardiography (if not previously performed). Selected subjects will then be recruited to undergo right heart catheterization. The goals of the study are to establish a pulmonary hypertension cohort for translational investigations, to determine the utility of NT-proBNP as a biomarker of PAH, to determine clinical characteristics and relationship of lung function to PAH in COPD and HIV, and to establish a biorepository for mechanistic studies of PAH phenotypes.